The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 533 KB) and Technical Notes (PDF, 752 KB) pages.



Download and Print: Download Printer-friendly PDF Download data


Table 14.22

Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Both Sexes by Race
Histologya All Races White Black Asian/
Pacific Islander
American Indian
/Alaska Nativeb
Hispanicc
Count Percent Count Percent Count Percent Count Percent Count Percent Count Percent
Carcinoma (8010-8576) 21,869 97.2% 15,329 96.9% 2,818 98.3% 3,364 97.8% 195 96.1% 3,507 95.3%
Hepatocellular carcinomad (8170-8175) 16,940 75.3% 11,527 72.9% 2,381 83.1% 2,743 79.7% 154 75.9% 2,805 76.2%
Cholangiocarcinoma (8032-8033,8070-8071, 8140-8141,8160,8260, 8480-8481,8490,8560) 3,936 17.5% 3,095 19.6% 325 11.3% 465 13.5% 31 15.3% 541 14.7%
Other carcinomae 993 4.4% 707 4.5% 112 3.9% 156 4.5% - - 161 4.4%
Other specific carcinomaf 598 2.7% 434 2.7% 59 2.1% 98 2.8% - - 96 2.6%
Unspecified, Carcinoma, NOS (8010,8020-8022,8031, 8046,8050) 395 1.8% 273 1.7% 53 1.8% 58 1.7% - - 65 1.8%
Hepatoblastoma (8970) 213 0.9% 168 1.1% - - 25 0.7% - - 83 2.3%
Sarcomag 204 0.9% 160 1.0% 18 0.6% 23 0.7% - - 37 1.0%
Hemangiosarcoma (9120) 81 0.4% 66 0.4% - - - - - - - -
Other sarcomash 123 0.5% 94 0.6% - - - - - - 24 0.7%
Other specific types (8720,8980,8991,9061, 9064,9070-9071,9080, 9100) 40 0.2% 28 0.2% - - - - - - - -
Unspecified (8000-8004) 165 0.7% 129 0.8% - - 21 0.6% - - 43 1.2%
Totald 22,492 100.0% 15,815 100.0% 2,866 100.0% 3,440 100.0% 203 100.0% 3,680 100.0%

Footnotes:

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Percents may not sum to 100 due to rounding.

a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

d Epidermoid carcinoma arising from liver parenchyma are referred to as hepatocellular carcinoma.

e Other carcinoma include histologies 8010, 8012-8013, 8020-8022, 8031, 8035, 8041-8042, 8046, 8050, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

f Other specific carcinoma include histologies 8012-8013, 8035, 8041-8042, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

g Sarcoma includes histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9120, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

h Other sarcomas include histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

- Statistic not shown due to fewer than 16 cases during the time period.

Page Navigation: << Previous Next >>


The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.